567 reports of this reaction
1.4% of all RIVASTIGMINE reports
#20 most reported adverse reaction
PARKINSON^S DISEASE is the #20 most commonly reported adverse reaction for RIVASTIGMINE, manufactured by Sandoz Inc. There are 567 FDA adverse event reports linking RIVASTIGMINE to PARKINSON^S DISEASE. This represents approximately 1.4% of all 39,624 adverse event reports for this drug.
Patients taking RIVASTIGMINE who experience parkinson^s disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PARKINSON^S DISEASE is a less commonly reported adverse event for RIVASTIGMINE, but still significant enough to appear in the safety profile.
In addition to parkinson^s disease, the following adverse reactions have been reported for RIVASTIGMINE:
The following drugs have also been linked to parkinson^s disease in FDA adverse event reports:
PARKINSON^S DISEASE has been reported as an adverse event in 567 FDA reports for RIVASTIGMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PARKINSON^S DISEASE accounts for approximately 1.4% of all adverse event reports for RIVASTIGMINE, making it a notable side effect.
If you experience parkinson^s disease while taking RIVASTIGMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.